Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Exelixis, Inc. (EXEL) -- Ignore unavailable to you. Want to Upgrade?

To: keokalani'nui who wrote (309)	11/8/2006 12:02:28 PM
From: dr.praveen	Respond to of 930

As you know Anthracyclines cause LVEF reduction, or the more severe congestive heart failure (CHF) which might have likely added to the toxicity in AML pts being treated with 999. Doxorubicin is the better Anthracycline having less than 1% of SE if used under 550mg/m2.But don't know if the pts are treated with other Anthracyclines or with a diff doxorubicin dosage. I feel Exelixis might go with the lower dose rather than picking selective groups.